A5377
A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against the human immunodeficiency virus (HIV).
DURATION: April 2019 - Ongoing
STUDY TYPE: HIV Treatment
PHASE: 1
DESIGN: Randomized, parallel assigned, double masked interventional study
STATUS: Ongoing
ENROLLMENT: ≈84
POPULATION: People living with HIV, 18-70 years old
NUMBER OF SITES: 27
SITE LOCATIONS: US
NCT #: NCT03705169